SCOPUS 정보 검색 플랫폼

Volumn 37, Issue 1, 2001, Pages 13-25

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

(7) Sacchi, Stefano a Federico, Massimo a Dastoli, Giuseppe b Fiorani, Claudia a Vinci, Giovanni a Clò, Vera a Casolari, Barbara a

a UNIVERSITY OF MODENA AND REGGIO EMILIA (Italy)

b ROCHE MILANO RICERCHE (Italy)

Author keywords

Anti CD20; B Lymphoproliferative disorders; MAbs; NHL; Rituximab

Indexed keywords

ALPHA INTERFERON; CD20 ANTIGEN; COMPLEMENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON; PREDNISONE; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER REGRESSION; CYTOKINE RELEASE; DRUG INDICATION; EFFECTOR CELL; HUMAN; HYPOTENSION; IMMUNOTHERAPY; NONHODGKIN LYMPHOMA; REVIEW; SIDE EFFECT;

EID: 0035154779 PISSN: 10408428 EISSN: None Source Type: Journal
DOI: 10.1016/S1040-8428(00)00069-X Document Type: Article

Times cited : (42)

References (52)

1
- 0006452526
- The non-Hodgkin's lymphoma pathologic classification project, National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphoma. Summary and description of work formulation for clinical usage, Cancer 1982;49:2112-35.

2
- 0006414816
- Lennert K, Feller A, editors, Hystopatology of Non-Hodgkin's Lymphomas. New York: Springer Verlag, 1992.

3
- 0028064764
- A revised European American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group
- (1994) Blood , vol.84 , pp. 1361-1392
- Harris, L.H.¹ Jaffe, E.S.² Stein, H.³

4
- 0016756272
- Continuous cultures of fused cells secreting antibody of predefined specificity
- (1975) Nature , vol.256 , pp. 495-497
- Köhler, G.¹ Milstein, C.²

5
- 0031766682
- Monoclonal antibody-based therapies for hematologic malignancies
- (1998) J. Clin. Oncol. , vol.16 , pp. 3691-3710
- Pratik Multani, S.¹ Grossbard, M.L.²

6
- 0028012101
- Chimerization of antitumor antibodies via homologous recombination conversion vectors
- (1994) Cancer Res. , vol.54 , pp. 506-512
- Yarnold, S.¹ Fell, H.P.²

7
- 0342530626
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response
- (1989) Proc. Natl. Acad. Sci. , vol.86 , pp. 4220-4224
- LoBuglio, A.F.¹ Wheeler, R.H.² Trang, J.³

8
- 0028231359
- A phase 1 B trial of humanized monoclonal antibody M 195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity
- (1994) Blood , vol.83 , pp. 1760-1768
- Caron, P.C.¹ Jurcic, J.G.² Scott, A.M.³

9
- 0027092901
- Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies
- (1992) Cancer Res. , vol.52 , pp. 6761-6767
- Caron, P.C.¹ Co, M.S.² Bull, M.K.³

10
- 0023611311
- Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity
- (1987) J. Immunol. , vol.139 , pp. 3521-3526
- Liu, A.Y.¹ Robinson, R.R.² Murray E.D. Jr³

11
- 0028057250
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody CD20
- (1994) Blood , vol.83 , pp. 435-445
- Reff, M.E.¹ Carner, K.² Chambers, K.S.³

12
- 0025021639
- Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody
- (1990) J. Immunol. , vol.144 , pp. 1382-1386
- Mueller, B.M.¹ Romerdahl, C.A.² Gillies, S.D.³

13
- 0018949401
- Characterization of a human B lymphocyte specific antigen
- (1980) J. Immunol. , vol.125 , pp. 1678-1685
- Stashenko, P.¹ Nadler, L.M.² Hardy, R.³ Schlossman, S.F.⁴

14
- 0021272605
- Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation
- (1984) Blood , vol.63 , pp. 1424-1433
- Anderson, K.C.¹ Bates, M.P.² Slaughenhoupt, B.L.³ Pinkus, G.S.⁴ Schlossman, S.F.⁵ Nadler, L.M.⁶

15
- 0022370476
- The B cell surface molecule B1 is functionally linked with B cell activation and differentiation
- (1985) J. Immunol. , vol.135 , pp. 973-979
- Tedder, T.F.¹ Boyd, A.W.² Freedman, A.S.³ Nadler, L.M.⁴ Shlossman, S.F.⁵

16
- 0022510242
- Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
- (1987) Eur. J. Immunol. , vol.16 , pp. 881-887
- Tedder, T.F.¹ Forsgren, A.² Boyd, A.W.³ Nadler, L.M.⁴ Shlossman, S.F.⁵

17
- 0022202908
- The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle
- (1985) J. Immunol. , vol.135 , pp. 3795-3801
- Golay, J.T.¹ Clark, E.A.² Beverley, P.C.L.³

18
- 0005517434
- Role of the Bp35 cell surface polypeptide in human B-cell activation
- (1985) Proc. Natl. Acad. Sci. , vol.82 , pp. 1766-1770
- Clark, E.A.¹ Shu, G.² Ledbetter, J.A.³

19
- 0342530626
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response
- (1989) Proc. Natl. Acad. Sci. , vol.86 , pp. 4220-4224
- LoBuglio, A.F.¹ Wheeler, R.H.² Trang, J.³

20
- 0023976470
- Molecular cloning of the human B cell CD20 receptors predicts a hydrophobic protein with multiple transmembrane domains
- (1988) EMBO J. , vol.7 , pp. 711-717
- Einfeld, D.A.¹ Brown, J.P.² Valentine, M.A.³ Clark, E.A.⁴ Ledbetter, J.A.⁵

21
- 0023101978
- Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
- (1987) Blood , vol.69 , pp. 584-591
- Press, O.W.¹ Appelbaum, F.² Ledbetter, J.A.³

22
- 0006452902
- Golay J, Zaffaroni L, Borleri GM, et al. Rituximab and complement induced lysis of neoplastic B cells is regulated by CD55. Haematologica 1999; 84 (EHA 4 Abstract Book): Abs 0324.

23
- 0000652501
- Chimeric anti-CD20 antibody (IDEC-C2B8) is apoptotic and sensitizes drug-resistant human B-cell lymphomas and AIDS-related lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins
- (1995) FASEB J. , vol.9
- Demidem, A.¹ Hanna, N.² Hariharan, H.³ Bonavida, B.⁴

24
- 0006489944
- Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAB) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 83: Abs A 2535.

25
- 0028127304
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B cell lymphoma
- (1994) Blood , vol.84 , pp. 2457-2466
- Maloney, D.G.¹ Leles, T.M.² Czerwinski, D.K.³

26
- 0345337254
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
- (1998) J. Clin. Oncol. , vol.16 , pp. 2825-2833
- McLaughlin, P.¹ Grillo-Lopez, A.² Link, B.K.³

27
- 0006448531
- Maloney DG, Bodkin D, Grillo-Lopez AJ, et al. IDEC-C2B8: Final report on a phase II trial in relapsed non-Hodgkin's lymphoma. Blood 1994; 84 (Suppl. 1), Abs 661.

28
- 1842368507
- Initial report on a phase I/II multiple dose clinical trial of (IDEC-C2B8) (chimeric anti CD20) in relapsed B-cell lymphoma
- (1997) Blood , vol.90 , pp. 2188-2195
- Maloney, D.G.¹ White, C.² Bodkin, D.³

29
- 0006452903
- McLaughlin P, Grillo-Lopez AJ, Maloney DG, et al. Efficacy controls and long-term follow-up of patients (pts) treated with Rituximab for relapsed or refractory, low-grade or follicular (R-LG/F) NHL. Blood 1998; 92: (Suppl 1), Abs 1712.

30
- 0006411286
- Davis T, Levy R, White CA, et al. Rituximab: Phase II (PII) retreatment (ReRx) study in patients (pts) with low-grade or follicular (LG/F) NHL. Blood 1998; 92 (Suppl 1): Abs 1710.

31
- 0006412384
- Davis TA, White CA, Grillo-Lopez AJ, et al. Rituximab: first report of a phase II (PII) trial in NHL patients (pts) with bulky disease. Blood 1998; 92: (Suppl 1), Abs 1711.

32
- 0032530342
- Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
- (1998) Blood , vol.92 , pp. 1927-1932
- Coiffier, B.¹ Haioun, C.² Ketterer, N.³

33
- 0032931320
- IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients
- (1999) Eur. J. Haematol. , vol.62 , pp. 76-86
- Nguyen, D.T.¹ Amess, J.A.² Doughty, H.³ Hendry, L.⁴ Diamond, L.W.⁵

34
- 0006488939
- Link BK, Grossbard ML, Fisher RI, et al. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or high-grade NHL. Proc Am Soc Clin Oncol 1998; 17: Abs A7.

35
- 0006479135
- Byrd JC, Waselenko JK, Maneatis TA, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid tumor lysis. Blood 1998; 92 (Suppl. 1): Abs 432.

36
- 0006488940
- Rambaldi A, Manzoni C, Baccarani M, et al. t(14;18) positive follicular lymphoma: front-line treatment with CHOP and anti-CD20 (Rituximab) monoclonal antibody. Haematologica 1999; 84 (EHA 4 Abstract Book): Abs p 142.

37
- 0006488941
- Gianni AM, Magni M, Di Nicola M, et al. In vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with Rituximab and high-dose chemotherapy. Blood 1998; 92 (Suppl. 1): Abs 481.

38
- 0344766075
- Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
- (1999) J. Clin. Oncol. , vol.17 , pp. 268-276
- Czuczman, M.S.¹ Grillo-Lopez, A.J.² White, C.A.³

39
- 0006414817
- Davis T, Maloney D, White CA, et al. Combination Immunotherapy in low grade or follicular (LG/F) non-Hodgkin's lymphoma (NHL) with Rituximab and alpha interferon: Interim analysis. Proc ASCO 1998; 17: Abs 39.

40
- 0000443627
- Phase II study of Rituximab (IDEC-C2B8) after priming with IFN-(2a in patients with relapsed low-grade or follicular lymphoma
- (1999) Blood , vol.94 , Issue.1 SUPPL.
- Sacchi, S.¹ Federico, M.² Vinci, G.³

41
- 0006411287
- Sivaraman S, Venugopal P, Huang X, et al. Effect of in vitro exposure to interferon alpha (IFNα) on CD20 expression in chronic lymphocytic leukemia cells (CLL). Ann Oncol 1999;10: Abs 222.

42
- 0006480797
- Venugopal P, Sivaraman S, Huang X, et al. Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines. Blood 1998; 92 (Suppl. 1): Abs 1009.

43
- 0006495112
- Janakiraman N, McLaughlin P, White CA, et al. Rituximab: Correlation between effector cells and clinical activity in NHL. Blood 1998; 92: Abs 1384.

44
- 0006476827
- van der Kolk LE, Grillo-Lopez AJ, Gerritsen W, et al. Chimeric anti-CD20 monoclonal antibody (Rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial. Blood 1998; 92 (Suppl. 1): Abs 4037.

45
- 0006412192
- Flinn IW, O'Donnell SJ, Noga SJ, et al. In vivo purging and adjuvant immunotherapy with Rituximab during PBSC transplant for NHL. Blood 1998; 92 (Suppl. 1): Abs 2673.

46
- 0006480798
- Byrd JC, White CA, Link B, et al. Rituximab therapy in previously treated Waldenstrom's macroglobulinaemia: preliminary evidence of activity. Blood 1998; 92 (Suppl. 1): Abs 433.

47
- 0006457986
- O'Brien S, Freireich E, Andreeff M, Lerner S, Keating M: phase I/II study of Rituxan in chronic lymphocytic leukemia (CLL). Blood 1998; 92 (Suppl. 1): Abs 431.

48
- 0006488944
- Tsiara SN, Vartholomatos G, Kapsali H, et al. Monoclonal antibody, Rituximab, administration for the treatment of resistant B-prolymphocytic leukemia. Ann Oncol 1999; 10: Abs 467.

49
- 0006480799
- Milpied N, Antoine C, Garnier JL, et al. Humanized anti CD-20 monoclonal antibody (Rituximab) in B postrasplant lymphoproliferative disorders (B PTLDs): a retrospective analysis of 32 patients. Ann Oncol 1999; 10: Abs 11.

50
- 0006495486
- Pavlick A, Markowitz J, Goldstein M, et al. Treatment of post-transplant lymphoproliferative disorder (PTLD) with IDEC Anti-CD20 antibody (Rituximab). Ann Oncol 1999; 10: Abs 648.

51
- 0006448532
- Grillo-Lopez AJ, Lynch J, Coiffier B, et al. Rituximab therapy of lymphoproliferative disorders in immunosuppressed patients (pts). Ann Oncol 1999; 10: Abs 662.

52
- 0032212275
- Rituxan in the treatment of cold agglutinin disease
- (1999) Blood , vol.92 , pp. 3490-3491
- Lee, E.J.¹ Kueck, B.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.